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Abstract
Background: It has been proposed that artemisinin-based combination therapy (ACT) be subsidised in the private sector in
order to improve affordability and access. This study in western Kenya aimed to evaluate the impact of providing subsidized
artemether–lumefantrine (AL) through retail providers on the coverage of prompt, effective antimalarial treatment for
febrile children aged 3–59 months.
Methods and Findings: We used a cluster-randomized, controlled design with nine control and nine intervention
sublocations, equally distributed across three districts in western Kenya. Cross-sectional household surveys were conducted
before and after the delivery of the intervention. The intervention comprised provision of subsidized packs of paediatric ACT
to retail outlets, training of retail outlet staff, and community awareness activities. The primary outcome was defined as the
proportion of children aged 3–59 months reporting fever in the past 2 weeks who started treatment with AL on the same
day or following day of fever onset. Data were collected using structured questionnaires and analyzed based on cluster-level
summaries, comparing control to intervention arms, while adjusting for other covariates. Data were collected on 2,749
children in the target age group at baseline and 2,662 at follow-up. 29% of children experienced fever within 2 weeks before
the interview. At follow-up, the percentage of children receiving AL on the day of fever or the following day had risen by
14.6% points in the control arm (from 5.3% [standard deviation (SD): 3.2%] to 19.9% [SD: 10.0%]) and 40.2% points in the
intervention arm (from 4.7% [SD: 3.4%] to 44.9% [SD: 11.7%]). The percentage of children receiving AL was significantly
greater in the intervention arm at follow-up, with a difference between the arms of 25.0% points (95% confidence interval
[CI]: 14.1%, 35.9%; unadjusted p=0.0002, adjusted p=0.0001). No significant differences were observed between arms in
the proportion of caregivers who sought treatment for their child’s fever by source, or in the child’s adherence to AL.
Conclusions: Subsidizing ACT in the retail sector can significantly increase ACT coverage for reported fevers in rural areas.
Further research is needed on the impact and cost-effectiveness of such subsidy programmes at a national scale.
Trial Registration: Current Controlled Trials ISRCTN59275137 and Kenya Pharmacy and Poisons Board Ethical Committee for
Clinical Trials PPB/ECCT/08/07.
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Artemisinin-based combination treatments (ACTs) are generally
accepted as the best treatment for uncomplicated Plasmodium
falciparum malaria, as they have been shown to be highly effective
and generally well tolerated [1]. Consequently all P. falciparum–
endemic countries in Africa have adopted ACTs as national
policy, but usage remains very low, with only 16% of febrile
children under the age of 5 years receiving ACTs in 2008 [2]. A
large gap therefore exists between the target, set by the Roll Back
Malaria Partnership, that 80% of malaria cases be treated with
effective treatment within 24 hours, and the situation on the
ground [2].
There have been calls for radical solutions to improve access to
effective malaria treatment. Prominent among these is a proposal
to subsidize ACTs in the private sector [3]. The private sector is an
important source of malaria drugs [4,5], but the high retail price of
ACTs has resulted in continued use of more affordable but less
effective antimalarial drugs in this sector such as sulphadoxine–
pyrimethamine (SP) and amodiaquine [6].
An ACT subsidy mechanism known as the Affordable
Medicines Facility-malaria (AMF-m) is currently being established,
managed by the Global Fund for HIV/AIDS, TB and Malaria.
The Global Fund will make copayments directly to preselected
ACT manufacturers, lowering the import cost for both public and
private sector buyers. The aim is to reduce ACT retail prices to a
level similar to less effective antimalarials, to increase demand for
ACTs and displace monotherapies and substandard treatments
from the market. Additional funding is to be made available to
countries for ‘‘supporting interventions’’ such as community
awareness, provider training, and regulatory strengthening.
AMF-m is scheduled to roll out in eight Phase One countries
(Cambodia, Ghana, Kenya, Madagascar, Niger, Nigeria, Uganda
and the United Republic of Tanzania [mainland and Zanzibar])
[7].
Limited experience with private-sector ACT subsidies indicates
that they can lead to increased ACT uptake and decreased
monotherapy use [8,9]. No data, however, are available on the
impact on the key outcome of coverage of prompt effective
treatment of fever at the community level. With only a subset of
the community using retail outlets, it is not clear if an intervention
targeting retailers only will demonstrate a significant effect on
overall treatment coverage. In addition, there are concerns that
shopkeepers may not stock the subsidized medicines due to capital
constraints; that brief training may be insufficient to change
treatment practices; and that retailers may not pass on the subsidy
to the consumer, preferring instead to maximize their profits. Also
it is not known whether caretakers of young children will be willing
to change their treatment practices and to trust shopkeepers to
provide good-quality ACTs. Finally, there are concerns that the
subsidies will be taken advantage of by the relatively well-off, with
the poorest in the community unable to afford even the subsidized
ACTs [9–14].
Here we report a cluster randomised trial to address these gaps
in knowledge, evaluating the impact of a package including ACT
subsidies, retailer training, and community awareness on ACT
coverage, price, and adherence in a high malaria transmission area
of western Kenya.
Methods
Ethical Approval
Ethical approval was obtained from the Kenya Medical
Research Institute (KEMRI) Ethical Review Committee (#
1361), the Kenya Pharmacy and Poisons Board Ethical Commit-
tee for Clinical Trials (# PPB/ECCT/08/07), and the London
School of Hygiene and Tropical Medicine Ethical Review
Committee (# 5288). The study is registered with Current
Controlled Trials (# ISRCTN59275137). Written consent was
obtained from the household heads or a representative, and verbal
consent was obtained from all caregivers interviewed. Ethics
statement: ‘‘We (the KEMRI National Ethics Review Committee)
acknowledge the receipt of Teso, Samia and Wanga- translated
Informed Consent Documents. The committee is satisfied with the
contents which assures the understanding of potential research
participants. The study is hereby granted [ethical] approval.’’
Study Overview
The study was conducted in Kenya, where the first-line
antimalarial for uncomplicated cases is artemether–lumefantrine
(AL). AL is a prescription-only medicine, officially available at
registered health facilities and pharmacies only, although in
practice many prescription-only drugs are dispensed without a
prescription in pharmacies and other retail outlets. It has a private
sector retail price of around 6.16 US dollars (USD) (500 Kenya
Shillings [KSH]), compared with an average of around 0.37 USD
for common older antimalarials such as SP and amodiaquine
(based on USD-to-KSH exchange rate for 1st November 2008
when the subsidized drugs were first distributed [15]). As a
comparison, in Kenya, the poverty line (the cost of a basic basket
of food and non-food items) in 2003 was about 1,239 KSH (15.25
USD) per person per month for rural inhabitants [16]. The pilot
was implemented by a team from Division of Malaria Control in
the Kenyan Ministry of Public Health and Sanitation, Population
Services International (PSI), and the Pharmacy and Poisons Board
(PPB).
Study Sites
The study was conducted in three districts in Kenya’s Western
Province: Busia, Butere-Mumias, and Teso (for maps of study
areas see Figures S1 and S2). These areas were selected because of
their high malaria endemicity [17], the presence of a relatively
active retail market, and the absence of other retail sector malaria
treatment interventions.
At the time of the survey, the percentage of the population living
below the poverty line in the study districts averaged 67% in Busia,
62% in Butere-Mumias, and 50% in Teso. Population densities
per km
2 were 433, 611, and 406 in Busia, Butere-Mumias, and
Teso, respectively [18]. This area suffers from the highest malaria
prevalence in Kenya, with Plasmodium falciparum parasitaemia
prevalance in children aged 2–10 years being 40% or more [17].
At the time of the survey, Butere-Mumias had 51 government
health facilities, Busia 39, and Teso 21, consisting of dispensaries,
health centres, and one district hospital per district [19]. All
government health facilities in Kenya are supposed to supply AL
free to patients, although stock-outs and unofficial fees are
common [20,21]. Malaria diagnosis is predominantly presump-
tive, based on the presence of fever, in both public and private
health sectors [22,23].
Study Design
We employed a cluster randomised controlled design, collecting
data before (at baseline) and after (at follow-up) the roll out of the
intervention. Randomization was conducted at the sublocation
level, which is the fifth and lowest administrative level in Kenya,
governed by a subchief. To be included in the sampling frame the
sublocations had to have populations between 2,500 and 10,000;
smaller sublocations were excluded to ensure there was a
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the evaluation; larger sublocations were excluded to contain the
costs. Urban and periurban sublocations, which represented
between a quarter and a third of all sublocations in the study
districts, were excluded from the sampling frame because of the
high likelihood of contamination when people from surrounding
sublocations travelled to purchase antimalarials in urban areas. A
modified randomization process was used to select sublocations. A
random list of all eligible sublocations was formulated per district
in Microsoft Excel. The first intervention sublocation was selected
from the top of the list. In order to reduce the potential for
contamination a ‘‘buffer zone’’ was created where all sublocations
located within two sublocation boundaries of the selected
sublocation were removed from the list. The list was reshuffled
randomly and the first sublocation on the new list allocated to the
control arm. The same procedure of creating a buffer zone around
this sublocation was carried out, and the list again randomly
reshuffled and a second intervention sublocation selected. This
process was continued, alternating between the selection of
intervention and control sublocations, until three intervention
and three control sublocations had been selected within the
district. The estimated population in the control and intervention
arms were 38,620 and 44,538, respectively (average population
per selected sublocation of 4,620, range 2,703 to 9,294) [18]. Due
to the public information campaign around the subsidised drugs in
the intervention arm, blinding was not possible for shopkeepers,
community members, or data collectors.
The Intervention
The three main components of the intervention were provision
of subsidized packs of paediatric ACT to retail outlets, training of
retail outlet staff, and community awareness activities. No
interventions were implemented in the control arm. In both
intervention and control arms the policy of provision of free AL at
government facilities continued unchanged. In 2006/7 the
government had carried out AL awareness campaigns across the
country, so both arms had previously received some general
information on the current malaria treatment policy (personal
communication, Andrew Nyandigisi, Division of Malaria Control,
Ministry of Public Health and Sanitation Kenya).
The intervention targeted retail outlets serving intervention
arms, which were identified through an outlet census. Outlets were
included in the census if they were located in or on the borders of
the intervention sublocations and identified by key informants as
serving their populations. An initial list of retail outlets was sourced
from local public health officers, and updated with input from
local chiefs and subchiefs. The list was further amended after
walking around the study areas with village elders to confirm the
presence of outlets and to add missed outlets. The snowball
technique [24] was then used where each shop visited was asked
about the presence of other outlets in their area. Finally, members
of the community passing by were opportunistically asked about
the location of outlets.
Enumerated outlets were invited for training if they had been
functioning for a minimum period of six months and were selling
antimalarials and/or antipyretics during the past year. A total of
225 outlets were deemed eligible for training, of which 61 were
specialised drug stores (registered or unregistered pharmacies) and
164 general stores (which sold medicines alongside general
household goods). Outlet staff attended a one-day malaria-related
training between August and October 2008 covering clinical
diagnosis, treatment, adverse drug reactions (ADRs), and patient
referral. Training materials were developed by the implementation
team, building on those used previously for shopkeeper training in
Kenya [25]. At follow-up in the intervention arm, 320 outlets met
the above eligibility requirements and were successfully inter-
viewed, of which 136 reported having at least one staff member
trained (43%) (Figure 1) [26].
From November 2008, subsidised AL was provided to trained
retail outlets in packs of six tablets (for children aged 3–35
months) and 12 tablets (for children aged 36–59 months). The AL
was branded as Tibamal, a pretested name derived from the
Kiswahili words ‘‘Tiba ya Malaria,’’ meaning malaria cure, and
came with patient instructions suitable for those with low literacy
levels. Kiswahili is one of the official languages of Kenya which is
commonly understood by all tribal groups in the country,
including those participating in the study. The PPB granted
special dispensation for AL to be dispensed over the counter in
the intervention arm. PSI sales staff delivered the treatment
directly to the trained outlets on a monthly basis, and
shopkeepers purchased the treatment at a wholesaler price of
0.10 USD (8 KSH) per pack (both packs were the same price).
The outlets were instructed to sell the packs at a retail price of
0.25 USD (20 KSH), and this price was printed on the drug
packaging. This provided a retail mark-up of 0.15 USD (12 KSH)
per pack. The intervention was designed to give Tibamal a 150%
retailer markup, exceeding that of other popular antimalarials
such as amodiaquine and SP, which generally have mark-ups of
50%–100%.
At baseline AL was stocked in only 0.5% of outlets in the control
arm and 2.4% in the intervention arm. At follow-up, AL
(including Tibamal) was stocked by 37.6% of outlets in the
intervention arm but only 5.5% in the control arm. No stocks of
Tibamal were found in the control arm; however, in the
intervention arm, Tibamal was present in 35% of outlets. In the
subsample of Tibamal trained outlets, 72% were found to be
stocking AL, 69% of which was Tibamal branded AL. The
median cost of a tablet of AL at baseline was 0.18 USD in the
control arm; by follow-up this had fallen slightly to 0.14 USD. In
the intervention arm the cost of an AL tablet fell from 0.15 USD at
baseline to 0.04 USD at follow-up, a difference of 0.11 USD.
Availability of other ACTs in retail outlets was rare at both time
points. The price for other ACTs was similar to commercial sector
AL [26].
Trained outlets were supplied with job aids, consisting of a
referral flow chart and dosing guidelines, to support dispensing.
Shopkeepers were also supplied with a Daily Activity Register to
document AL dispensed, and forms for referring severe cases and
suspected ADRs to local health facilities. Copies of completed
referral forms were to be collected by PSI sales staff and forwarded
to the PPB. All supporting materials supplied to outlets were
provided free of charge. A follow-up supervisory visit was made by
the implementation team 3 months after the initial supplies to
monitor outlet practices.
The main community awareness activities began in March
2009, and then intermittently in August and September 2009.
Activities were to continue to the end of the pilot in May 2010.
They consisted of nine community leader workshops that targeted
47 people; nine community events carried out by PSI that targeted
11,500 people; ten small group discussions that targeted 200
people; and outreaches carried out by community-based organi-
sations that targeted 21,000. These activities were designed to
make the community aware of malaria, the availability of
Tibamal, and the importance of adherence to the medication.
Tibamal was also advertised through posters and paintings on
shops that sold the treatment. Tibamal branded headscarves, t-
shirts, and pens were also freely distributed to the intervention
community.
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The primary outcome was defined as the proportion of
children aged 3–59 months reporting fever in the past 2 weeks
who started treatment with AL on the same day or following day
of fever onset. Secondary outcomes included the adequacy of AL
doses obtained and consumed, and the price paid per pack.
These were assessed using pre- and post-household surveys
conducted in July–August 2008 and July–August 2009. The study
was based on an intention to treat analysis where clusters were
not adjusted or further selected depending on the proportion of
retail outlets which actually received the intervention. The
sample size was based on detecting a 20% point difference in
the primary outcome, with 5% significance, 80% power, and an
estimated design effect of 2 to account for the cluster survey
design (percentage point refers to the absolute difference observed
between two percentages, in this case between the outcome
percentages observed between the intervention and control arm).
We estimated that the primary outcome would be 20% at
baseline (based on data collected by Gitonga et al. [27], and
allowing for some increase since that survey took place). A design
effect of 2 was considered conservative based on an intra-class
correlation coefficient of 0.16 from a similar previous survey in
Kenya [28], and an estimated 43 homesteads per cluster. This led
to a required sample size of 158 childhood fevers in each arm,
which we estimated would require data collection from 1,138
homesteads in each arm, equivalent to around 210 households
per sublocation. A homestead is a group of households within the
same compound belonging to a single extended family. A
household consists of a person or a group of related or unrelated
persons who live together in the same dwelling unit, who
acknowledge one male or female as the head of the household,
who share the same housekeeping arrangements, and who are
considered to constitute one unit. A homestead can contain one
or more households.
Three enumeration areas (EAs) were randomly selected within
each intervention and control sublocation on the basis of
probability proportional to population size. A homestead census
was carried out in the selected EAs in May 2008 and each
homestead was mapped using GPS hand-held receivers (Garmin
etrex and Trimble 12 band GPS units). From the homesteads
enumerated, an average of 43 were randomly selected using simple
randomisation with Excel 2007, within each EA. To achieve the
sample size, homesteads selected for sampling but not available
during data collection were replaced by the next available from a
randomly ordered list of homesteads, formulated during the
census. A pretested questionnaire was administered to all
household heads within the selected homesteads to ascertain
household socioeconomic status, and to all caregivers of children
under 5 years of age reporting fever episodes in the 2 weeks prior
to the interview to assess treatment-seeking behaviour and
medicine use. All homesteads agreeing to participate at baseline
were revisited at follow-up. All households within each homestead
were interviewed at each time point, including new households
that were established at follow-up.
Figure 1. Flow diagram showing households and retail outlets sampled and interviewed.
doi:10.1371/journal.pmed.1000437.g001
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Baseline data were captured on paper questionnaires and
double entered into Microsoft Access (2007). Follow-up data were
captured using personal digital assistants and Pendragon Forms
version 5.1 (Pendragon Software Corporation, Libertyville,
Illinois [http://www.pendragon-software.com] and downloaded
onto Microsoft Access [2007]). The data were analyzed in
STATA (College Station, Texas) by a two-stage process, with
baseline and postintervention data analyzed separately. In the
first stage a summary cluster measure was obtained for each
cluster. The second stage involved comparing the sets of cluster-
specific measures in control and intervention arms at follow-up
using the unpaired t-test [29]. A crude analysis was carried out on
the cluster summaries using the simple two tailed t-test to obtain
the means, 95% confidence intervals (CIs) and standard
deviations (SDs) for the outcome of interest. In addition, an
adjusted analysis was carried out at follow-up on all indicators
using an individual level logistic regression run on the pooled data
set (control and intervention arms). To control for potential
confounders, the following covariates were considered: patient
age and sex, caretaker’s and household head’s education level,
wealth score, bed net use last night, district, and, when adjusting
for the adequacy of AL doses obtained and consumed, the source
of treatment. All covariates significant at a p-value of 0.2 in the
bivariate analysis were entered into the regression model.
Baseline values for the outcome in question were also included
as covariates if a difference of 5% points or more was observed
between the arms at baseline. The intervention status of the
cluster was not included in the logistic regression model. Rather,
the regression model provided the predicted outcome in the
absence of the intervention effect. Mean predicted and observed
outcomes were obtained per cluster and residuals were obtained
by subtracting the predicted outcomes from those observed in
each cluster. The t-test was used on these residuals to assess the
intervention effect, adjusted for the covariates included in the
logistic regression model. The t-test was used for both crude and
adjusted analyses, as it has been shown to be highly robust even
for small numbers of clusters. A separate analysis allowing for
clustering within homesteads was also conducted.
The presence of certain household assets (selected on the basis
of those included in the 2003 Kenyan Demographic and Health
survey [30]) was recorded to assess the wealth of the household.
A wealth index was constructed by assigning weights to each
asset using principal components analysis (PCA) with weights
based on the first principal component only [31]. Each
household was then assigned to a specific wealth quintile, from
most poor through to the least poor. All interviewed households
were included in the PCA, regardless of whether they contained
children aged under 5. The PCA was conducted separately for
baseline and follow-up surveys. In the analysis we tested for
heterogeneity in the effect of the intervention across the wealth
quintiles using ANOVA on the cluster percentages for the
primary outcome.
Results
Characteristics of Sampled Children
We completed interviews in 2,319 homesteads at baseline (3,288
households), and 2,204 homesteads at follow-up (3,182 house-
holds). Data were collected on 2,749 children aged 3–59 months at
baseline (1,381 and 1,368 in the control and intervention arms
respectively), and 2,662 at follow-up (1,305 and 1,357 respectively)
(Table 1). Around half the children were male. Just under half had
slept under an insecticide-treated net (ITN) the night before the
interview at baseline, and just over half at follow-up. Reported
fever within 2 weeks prior to the interview ranged from 26% in the
control arm at baseline to 32% in the intervention arm at follow-
up. Around half the household heads for the sampled children had
completed primary school or above. Within each arm, sampled
children were relatively equally distributed across the different
wealth quintiles. Fewer homesteads needed to be visited to find
one childhood fever than originally estimated, resulting in more
fevers being detected than expected from the sample size
calculations.
Table 1. Characteristics of surveyed children aged 3–59 months (mean of cluster summaries from the nine intervention and nine
control clusters).
Characteristic Baseline Follow-Up
Control, % (SD) Intervention, % (SD) Control, % (SD) Intervention, % (SD)
Total children present in interviewed households 1,381 1,368 1,305 1,357
Percentage of children aged $36 months 40.6 (3.8) 39.6 (2.1) 43.1 (4.1) 42.1 (3.3)
Male 50.5 (3.6) 53.1 (3.9) 51.6 (3.4) 52.1 (2.9)
Household heads had completed primary
school or above
54.7 (8.5) 47.8 (6.9) 53.2 (9.4) 47.5 (8.4)
Slept under an ITN last night 49.7 (9.2) 46.2 (5.6) 57.1 (7.7) 57.8 (10.3)
Wealth quintile
a
Quintile 1 (most poor) 20.6 (8.9) 21.9 (6.3) 20.1(8.6) 23.6 (7.2)
Quintile 2 (very poor) 22.7 (9.3) 21.3 (7.6) 22.3 (8.2) 23.2 (8.8)
Quintile 3 (poor) 18.0 (3.8) 21.0 (4.5) 19.0 (5.0) 20.1 (5.7)
Quintile 4 (less poor) 19.6 (6.8) 19.8 (7.2) 18.7 (10.6) 19.5 (9.7)
Quintile 5 (least poor) 19.1 (6.9) 16.0 (4.5) 19.9 (8.7) 13.3 (4.6)
Fever prevalence within the past 2 weeks 26.0 (8.6) 30.3 (8.7) 27.0 (7.4) 32.4 (10.3)
aWealth quintiles are based on all households interviewed. The percentages represent the number of households with children 3-59 months that fall within each
quintile.
doi:10.1371/journal.pmed.1000437.t001
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More than 86% of children who experienced a fever within 2
weeks of the interview had some kind of action taken by the
caregiver to treat the fever, with no significant difference seen at
follow-up across the two arms (Table 2). A total of 779 actions
were taken at baseline across both arms, and 728 at follow-up
(some caregivers took more than one action for a given fever). Of
all actions taken, the most common were visits to government
facilities and specialised drug stores (each accounting for around a
third of actions) (Table 3). These were followed by visits to general
stores and missionary/private health facilities, with use of
traditional healers very rarely reported. At follow-up, there was
no significant difference in the kind of actions taken across the two
arms. An increase was seen in the number of visits to general stores
and a decrease in visits to specialised drug outlets from baseline to
follow-up; however, this change in behaviour was observed in both
arms. When the analysis was restricted to first actions only, similar
patterns were observed.
Antimalarials Obtained
There was an increase in children receiving antimalarial
treatments from baseline to follow-up of 11.4% points in the
control arm and 18.5% points in the intervention arm, with a
significant difference at follow-up between the two arms (difference
in means: 13.7%: 95% confidence interval [CI] 2.5, 24.9;
unadjusted p=0.0192; adjusted p=0.0074) (Table 2).
The percentage of children receiving an antimalarial mono-
therapy (mainly amodiaquine, SP and quinine) fell by 7.0% points
in the control arm and 26.6% points in the intervention arm
(Table 2). At follow-up, the percentage of children receiving an
antimalarial monotherapy in the intervention arm was lower than
that in the control arm, although this was only of borderline
significance in the adjusted analysis (difference in means: 210.5%:
95%CI: 23.9%, 216.9%; unadjusted p=0.0036; adjusted
p=0.0518). Of those receiving monotherapies, few received an
artemisinin monotherapy (an average of 1% at baseline and 0.2%
at follow-up). The percentage receiving any brand of AL rose by
17.5% points in the control arm and 46% points in the
intervention arm, and the percentage of children at follow-up
receiving any brand of AL in the intervention arm was
significantly greater than in the control (difference in means:
26.4%: 95%CI: 12.6%, 40.2%: unadjusted p=0.0009; adjusted
p=0.0001) (Table 2). The increase in children receiving AL in the
intervention arm was largely due to the uptake of Tibamal, which
made up 63% of all AL received in this group. No caregivers
reported purchasing Tibamal in the control arm. Of all those
children who received any brand of AL, including Tibamal, a
significant proportion received it either on the same day or
following day of the fever developing (see Table 4 for results by
cluster). The percentage of children receiving AL on the same day
or the following day of the fever developing in the intervention
arm at follow-up was significantly greater than in the control arm,
with a difference between the arms of 25.0% points (95%CI:
14.1%, 35.9%; unadjusted p=0.0002, adjusted p=0.0001)
(Table 2). This represents a substantial increase for this primary
outcome, with the percentage of children receiving prompt AL
treatment in the intervention arm being more than double that in
the control arm at follow-up. There seemed to be no correlation
between increasing wealth and the probability of receiving any
brand of AL (p=0.8749) or Tibamal (p=0.7445) on the same day
or following day of fever developing (Table 2, refer to footnotes).
The variance observed between clusters was not large enough to
warrant a weighted analysis (Table 4) [29]. Only 5.5% of
homesteads had more than one child with fever in the past 2
weeks; allowing for homestead level clustering in the logistic
regression did not affect the adjusted estimates (unpublished data).
We investigated the percentage of actions by source which
resulted in any brand of AL being obtained on the same day or
following day of fever developing (Figure 2), but did not assess the
significance of difference between the arms at follow-up since the
study was not powered for this subanalysis. AL dispensing at
general stores increased from 0% to 63% from baseline to follow-
up in the intervention arm, while no AL was dispensed in control
arm outlets at baseline or follow-up. Similarly, in specialised drug
stores, in the intervention arm AL dispensing increased by 65%
points from baseline to follow-up (0% to 65%) compared to only a
10% point increase in the control arm (1% to 11%). Substantial
increases were also seen at government facilities and private/
mission facilities, but similar increases were observed in both arms
(Figure 2).
Accuracy of AL Doses Obtained and Consumed
Caregivers were asked to state the number of tablets they were
provided with and the number their child consumed. Accuracy of
dose obtained was defined as obtaining at least the correct number
of tablets for their child’s age. Accuracy of dose consumed was
defined as reporting consumption of exactly the correct number of
tablets for the child’s age within 3 days of receiving the medication.
We did not assess the precise timing of tablet consumption within
this 3 day period due to the challenges of obtaining accurate recall.
Of all children receiving AL, just under 70% of children in both
arms obtained an accurate dose at baseline (control 69.9% [SD:
33.8%]; intervention 68.6% [SD: 35.9%]), and just over 70% at
follow-up (control 71.6% [SD: 20.9%]; intervention 76.9%
[SD7.2%]). No significant difference was recorded at follow-up
between the two arms (difference in mean 5.3%: 95% CI 20.9%,
210.3%; unadjusted p=0.4836; adjusted p=0.6545) (Table 5). Of
all children obtaining AL, at baseline a correct dose was consumed
by 40.5% (SD: 23.3%) in the control group and 53.1% (SD:
40.2%) in the intervention group. At follow-up this rose to 49.4%
(SD: 24.8%) in the control arm and 67.0% (SD: 8.5%) in the
intervention arm, but the difference was not significant at the 5%
level (unadjusted p=0.0606; adjusted p=0.1095) (Table 5). In the
intervention arm, 80.6% (SD: 9.6%) of caregivers received the
correct dose of Tibamal for their child at follow-up compared to
70.7% (SD: 17.8) receiving the correct dose of any other brand of
AL. Adherence to Tibamal at follow-up in the intervention arm
was 71.8% (SD: 11.8%) compared to adherence to any other
brand of AL at 61.1% (SD: 22.5%).
Price Paid for Subsidised AL
95.3% (SD: 5.9%) of caregivers in the intervention arm at
follow-up who bought Tibamal said they purchased it at the
recommended retail price of 0.25 USD. Of those not paying this
price, three paid less than 0.25 USD and five paid between 0.31
USD and 1.23 USD.
Discussion
There has been considerable debate about how access to and
quality of malaria treatment can be improved [3,10,11,13,14].
This study shows that a suite of ACT subsidies, retailer training,
and community awareness activities can lead to substantial
improvement in the uptake of prompt effective treatment for
febrile children in rural Kenya. Although coverage still fell well
below the 80% target set by the RBM, the percentage of children
receiving AL during a fever episode in the intervention arm was
more than double that in the control arm at follow-up, with more
Access to Effective Malaria Treatment
PLoS Medicine | www.plosmedicine.org 6 May 2011 | Volume 8 | Issue 5 | e1000437Table 2. Antimalarial treatment obtained for children aged 3-59 months with fever in the previous 2 weeks (a comparison of the
nine intervention and nine control clusters).
Treatment-Seeking Behaviour Outcomes
Control
a (N=9), %
(SD)
Intervention
b
(N=9), % (SD)
Difference in Means
(95% CI)
p-Value
c, Unadjusted;
Adjusted
Children who had care sought for
them after developing fever:
Baseline 86.6 (6.4) 90.1 (4.7)
Follow-up 88.9 (4.3) 89.1 (4.9) 0.2 (4.8, 24.4) 0.9304; 0.8759
Children who received an antimalarial:
Baseline 38.9 (7.8) 45.5 (9.4)
Follow-up 50.3 (11.8) 64.0 (10.5) 13.7 (2.5, 24.9) 0.0192; 0.0074
Children who received an antimalarial monotherapy:
Baseline 29.8 (11.1) 39.0 (7.7)
Follow-up 22.8 (7.8) 12.4 (4.8) 210.4 (23.9, 216.9) 0.0036; 0.0518
d
Children who received any brand of AL:
Baseline 9.8 (8.3) 7.7 (5.1)
Follow-up 27.3 (15.2) 53.7 (12.3) 26.4 (12.6, 40.2) 0.0009; 0.0001
Children who received Tibamal:
Baseline 0 (0) 0 (0)
Follow-up 0 (0) 33.7 (6.8) 33.7 (28.8, 38.5) 0.0001; 0.0001
Children who received any brand of AL on the
same day or following day of fever onset:
e,f
Baseline 5.3 (3.2) 4.7 (3.4)
Follow-up 19.9 (10.0) 44.9 (11.7) 25.0 (14.1, 35.9) 0.0002; 0.0001
Children who received any brand of AL on the same
day or following day of fever onset, at follow-up,
by socio-economic status (wealth quintiles)
g:
Quintile 1 (most poor) 14.8 (20.6) 38.9 (18.3) 24.1 (4.6, 43.6)
Quintile 2 (very poor) 16.6 (16.9) 40.0 (22.1) 23.4 (3.7, 43.0)
Quintile 3 (poor) 16.6 (18.6) 50.8 (33.3) 34.2 (7.3, 61.2)
Quintile 4 (less poor) 21.7 (18.6) 43.8 (22.4) 22.1 (1.5, 42.7)
Quintile 5 (least poor) 15.4 (15.9) 47.8 (24.3) 32.4 (11.9, 52.9)
Children who received Tibamal on the same day or
following day of fever developing:
Baseline 0 (0) 0 (0)
Follow-up 0 (0) 29.7 (8.8) 29.7 (23.5, 35.9) 0.0001; 0.0001
Children who received Tibamal on the same day or
following day of fever developing at follow-up, by
socioeconomic status (wealth quintiles)
g:
Quintile 1 (most poor) 0 (0) 30.1 (14.3) 30.1 (40.2, 20.0)
Quintile 2 (very poor) 0 (0) 25.5 (19.9) 25.5 (39.6, 11.4)
Quintile 3 (poor) 0 (0) 30.4 (21.3) 30.4 (45.4, 15.3)
Quintile 4 (less poor) 0 (0) 32.5 (22.3) 32.5 (48.3, 16.8)
Quintile 5 (least poor) 0 (0) 20.8 (22.1) 20.8 (36.4, 5.2)
aTotal number of children with fever in the previous two weeks present in the control arm: Baseline=353; Follow-up=344.
bTotal number of children with fever in the previous two weeks present in the intervention arm: Baseline=413; Follow-up=417.
cp-Value: The p-value appearing first refers to the level of significance of the unadjusted difference between control and intervention arms at follow-up. The p value in
italics refers to the level of significance of the adjusted difference between the control and intervention arm at follow-up.
dThe reduced significance of the p-value after adjusting mainly reflects the significant negative relationship between baseline and follow-up values for this outcome.
This negative relationship is likely to be caused by a tendency for those already using some kind of antimalarial at baseline to be more likely to start using Tibamal at
follow-up (substituting one similarly priced product for another), as compared to those not using any antimalarial at baseline (for whom using Tibamal would
represent an increase in average expenditure compared with their baseline purchases).
eIntraclass correlation coefficient control arm: Baseline: 0.009, follow-up: 0.02; intervention arm: baseline: 0.01; follow-up: 0.01 (based on formulae provided in [53]).
fRank sum test: unadjusted analysis, p=0.0013; adjusted analysis, p=0.0003.
gTest for interaction between wealth quintiles and the intervention at follow-up: For the outcome ‘‘receiving any brand of AL on the same day or following day of fever
developing,’’ p=0.8749; for the outcome ‘‘receiving Tibamal on the same day or following day of fever developing,’’ p=0.7445.
N, number of clusters.
doi:10.1371/journal.pmed.1000437.t002
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receiving Tibamal, usually on the same day or the following day
after fever onset. This was accompanied by lower use of
antimalarial monotherapies at follow-up in the intervention group
compared with the control group, although this difference was
only of borderline significance. This is likely to have reflected
‘‘crowding out’’ of these antimalarials by the more effective
subsidised AL. However, it may also have reflected government
directives to phase out monotherapies such as amodiaquine at this
time (personal communication with PPB and local amodiaquine
manufacturer). In most cases, subsidised AL was purchased at the
recommended retail price.
The increase in AL coverage observed does not seem to have
resulted from a change in choice of providers, with treatment-
seeking patterns remaining similar between the intervention and
control arms. Instead, the intervention seems to have effected a
change in the type of drugs dispensed in specialised drug and
general retail outlets, with a major shift towards AL in both of
these provider types.
It was notable that a substantial increase was also seen in AL
coverage in the control arm between baseline and follow-up. This
is likely to have reflected a reduction in AL stock-outs at
government facilities between the two surveys in both arms. At
baseline, public sector AL stock-outs were common, with only one
third of facilities serving the study areas stocking both the 6- and
12-tablet packs of AL [20,32]. At follow-up this figure had almost
doubled to 65% [32]. This highlights that ensuring health facility
AL stocks is also essential for improving AL access. Given that the
study was carried out in the context of fluctuating supplies of AL at
government facilities, it is possible that the increase in coverage
from a subsidised retail sector intervention would be lower in a
context with reliable public sector antimalarial supplies. However,
it should be noted that government stock-outs of AL and other
essential medicines are common in Kenya and other African
countries, so this setting would not be considered atypical
[20,22,33,34].
In the intervention arm at follow-up, 77% of children receiving
AL obtained an accurate dose, and 67% consumed the correct
dose. No significant difference was observed in the accuracy of
doses obtained or consumed between Tibamal (obtained only from
retail outlets) and other AL brands (obtained mainly from
government and private/mission facilities), although there was
room for improvement in patient adherence to AL from both
sources. In comparison, a 2005 review looking at adherence in the
community to chloroquine, which also has a 3 day regimen,
showed only a median of one third using it correctly [35]. Other
studies on ACT adherence have shown varying results, ranging
from 39% to 90% [36–39], though the higher figures obtained in
some studies may reflect study designs where caretakers were
aware that their compliance would be monitored. There are a
number of limitations to the measurement of adherence used here
and in similar studies. It may be difficult for caregivers to recall
such details over a 2 week period, or they may deliberately
misreport tablet consumption if they are concerned about
revealing inappropriate dosing. Also, in formal health structures
such as government health facilities the child’s weight as opposed
to age may be used to determine the dose [40], so children who
did not fall into the standard weight range for their age may have
only seemed to have obtained the wrong number of tablets.
However, there are several reasons why adherence may truly have
been suboptimal, including poor knowledge of dosing regimens,
lack of advice from providers, and stock-outs of one of the AL pack
sizes meaning that children may have been sold an inappropriate
pack for their age. During focus group discussions, caregivers also
reported stopping medication as soon as the fever subsided, and
believing that the child’s recovery would hasten if the tablets were
given at more frequent intervals than stipulated in the dosing
regimen [41]. Interventions to improve adherence could include
reducing stock-outs of specific pack sizes, encouraging shopkeepers
to talk through the package dosing instructions with caretakers,
and the use of mass media to emphasise the importance of
completing the full dose [35].
Only one suspected ADR was reported through the retailer
referral forms for a child who had recently taken Tibamal. The
child was experiencing vomiting, shivering, and refusing to eat or
drink, and was referred to the nearest government health facility.
It was unclear whether the lack of other reported referrals reflected
a genuine lack of potential ADRs or a failure to report them.
During focus group discussions, caregivers and shopkeepers
commented that children who suffered any suspected ADRs from
Tibamal, or who did not get better, went directly to formal health
Table 3. Actions taken for treating children aged 3–59
months with fever in the previous 2 weeks (a comparison of
nine intervention and nine control clusters).
Care Sought
Control
(N=9) %
(SD), n
Intervention
(N=9), %
(SD), n
Difference
in Means
(95% CI)
p-Value
a,
Unadjusted;
Adjusted
Government
facility:
Baseline 32.6 (12.6),
119
27.6 (14.9),
137
Follow-up 36.4 (15.1),
118
29.0 (10.6),
116
27.4 (5.7,
220.4)
0.2483; 0.1018
Specialised drug
store:
Baseline 34.2 (12.9),
113
42.0 (13.1),
168
Follow-up 23.8 (9.1), 78 30.4 (16.6),
121
6.6 (20.0,
26.8)
0.3140; 0.3642
General store:
Baseline 10.9 (5.2), 41 13.5 (5.2), 55
Follow-up 20.3 (9.5), 67 27.2 (14.1),
115
6.8 (18.8,
25.1)
0.2442; 0.2158
Missionary/
private facility:
Baseline 7.4 (4.8), 24 8.7 (7.5), 30
Follow-up 9.3 (5.0), 30 5.4 (8.5), 19 23.9 (3.0,
210.9)
0.2504; 0.3208
Traditional
healers:
Baseline 0.5 (1.5), 1 0 (0), 0
Follow-up 0.7 (1.3), 2 0.6 (1.9), 2 0 (1.6, 21.7) 0.9794; 0.9994
Others
b:
Baseline 14.4 (5.8), 51 8.3 (7.3), 40
Follow-up 9.5 (6.3), 31 7.2 (3.9), 29 22.3 (2.9,
27.6)
0.3625; 0.6592
ap-Value: The p-value appearing first refers to the level of significance of the
unadjusted difference between control and intervention arms at follow-up.
The p-value in italics refers to the level of significance of the adjusted
difference between the control and intervention arm at follow-up.
bOthers include: prayers, treatment with Western medications present at home,
and treatment with home-made remedies.
n, Total number of visits; N, number of clusters.
doi:10.1371/journal.pmed.1000437.t003
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PLoS Medicine | www.plosmedicine.org 9 May 2011 | Volume 8 | Issue 5 | e1000437facilities, without going back to the retail outlets, meaning that
retailer referral forms may be inappropriate and/or unnecessary
for monitoring pharmacovigilance under retail distribution.
Other studies evaluating the effectiveness of distributing
subsidised ACTs through the private retail sector have shown
mixed findings. In pilot projects in Tanzania and Uganda there
Figure 2. Percentage of visits to different sources of care at which any brand of AL was dispensed on the same day or following day
of fever developing (a descriptive comparison between the nine intervention clusters and nine control clusters). Other includes
treatment at home with home-made remedies or Western medication, traditional healers, or prayers. Standard deviations for each facility: Baseline
control arm: government=20; SDS=4; GS=0; priv/miss=0; other=0. Baseline intervention arm: government=32; SDS=0; GS=0; priv/miss=33;
other=10; Follow up control arm: government=18; SDS=20; GS=0; priv/miss=49; other=36; Follow up intervention arm: government=18;
SDS=21; GS=25; priv/miss=53; other=34. Control, control arm; Govn, Government health facilities; GS, general stores; inter, intervention arm; Priv/
Miss, private or mission health facilities; SDS, specialised drug stores.
doi:10.1371/journal.pmed.1000437.g002
Table 5. Adequacy of AL doses obtained and consumed (mean of cluster summaries from nine intervention and nine control
clusters).
Adequacy
Control
a
(N=9), % (SD)
Intervention
b
(N=9), % (SD)
Difference in Means
(95% CI)
p-Value
c, Unadjusted;
Adjusted
Adequacy of dose obtained from the provider:
Baseline 69.9 (33.8) 68.6 (35.9)
Follow-up 71.6 (20.9) 76.9 (7.2) 5.3 (20.9, 210.3) 0.4836; 0.6545
Adequacy of dose administered:
Baseline 40.5 (23.3) 53.1 (40.2)
Follow-up 49.4 (24.8) 67.0 (8.5) 17.6 (36.1, 20.9) 0.0606; 0.1095
aTotal number of doses in the control arm: Baseline=26; Follow-up=89.
bTotal number of doses in the intervention arm: Baseline=30; Follow-up=221.
cp-Value: The p-value appearing first refers to the level of significance of the unadjusted difference between control and intervention arms at follow-up. The p value in
italics refers to the level of significance of the adjusted difference between the control and intervention arm at follow-up.
N, number of clusters.
doi:10.1371/journal.pmed.1000437.t005
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antimalarial monotherapies, with good adherence to target retail
prices [8,9,12]. By contrast, in Cambodia and Senegal, availability
of subsidised ACTs remained irregular, which was associated with
retail prices above the target level in Cambodia but not in Senegal
[12]. No other published data are yet available on the impact of
private sector ACT subsidies on coverage of prompt effective
treatment, and robust data on other strategies to improve ACT
coverage are limited [11]. There is however evidence that
provision of ACT through community medicine distributors
(CMDs) could also lead to high levels of ACT coverage, with a
multicountry study in Ghana, Nigeria, and Uganda finding that
59% of children reporting fever in the past 2 weeks had received
ACT from a CMD [42].
Several reviews have documented the challenges of drawing firm
conclusions about strategies to improve retail sector treatment
provision due to the limitations of existing studies, which often lack
adequate controls [10,11,43–45]. We selected a cluster randomized
design to significantly reduce the influence of chance, bias, or
confounding due for example to variations in public sector drug
stocks, weather patterns, and malaria awareness campaigns [46–
49]. While such randomized controlled trials are argued to have
high internal validity, there is concern that they may lack external
validity becausethestudy design demands implementation practices
that would be unrealistic in operational settings. In this study,
implementation was relatively typical of routine practices, without
the insistence on ‘‘ideal’’ delivery and adherence required in clinical
efficacy trials. However, the need to avoid contamination of control
sublocations meant that drug delivery and consumer education had
to be modified from standard practices. The implications of this are
discussed further below, where we consider likely differences
between the Tibamal intervention, and the AMF-m.
A number of other potential weaknesses in the study should be
highlighted. The analysis was carried out as two separate cross-
sectional surveys and did not adjust for children who may have
had fever at both survey time points. This may have resulted in an
underestimation of the primary outcome; however, we believe that
any possible underestimation as a result should be relatively small.
A limited degree of clustering occurred within homesteads within
survey rounds, but this did not affect the estimates. Contamination
is an important risk in study designs of this kind, and we therefore
investigated the exposure of households in the control arm to the
intervention. No children in the control arm were reported to have
received Tibamal at follow-up (Table 2). In addition, at follow-up
82% of caregivers in the intervention arm had heard of Tibamal,
compared to only 7% in the control arm [26].
The comparison of the suite of interventions with the control
does not allow us to isolate the contribution of each component.
However, we consider this appropriate given the consensus in the
literature that interventions of this kind need to be multifaceted,
incorporating both consumer- and provider-focused strategies
[10,50,51].
Care should be taken in extrapolating or generalising these
findings. This study was undertaken in three districts, all within
one province in Kenya, and was restricted to rural areas, so the
generalisability of the results to other areas should be carefully
considered. In some respects these districts can be considered
relatively representative of Kenya as a whole. For example, the 2
week fever prevalence, ITN use, and education levels reported in
this study are similar to those reported in national surveys [52].
58% of households in the control arm and 60% in the intervention
arm were classified as poor, compared to a national average of
54% [18]. However, this area has very high levels of malaria
endemicity compared with the rest of the country, and a relatively
active retail drugs market, with many specialised drug stores.
Although treatment-seeking patterns for fever in Kenya can be
considered relatively typical of sub-Saharan Africa, there are
important variations between countries in the share of treatment
sought in the retail sector and the nature of retail outlets providing
drugs [4,10]. Since follow-up data were collected only 8 months
after Tibamal distribution began and 4 months after the start of
community awareness activities, it is not known if Tibamal uptake
would stabilise or increase as consumers and providers become
more familiar with the medication over time.
In addition, there are a number of differences between this pilot
and the planned AMF-m roll-out, meaning that the results should
be used with caution for predicting AMF-m impact. This
intervention was targeted at children aged 3–59 months only,
but under AMF-m subsidised drugs will be available to all age
groups. Under AMF-m subsidised drugs will be distributed
through existing private and public sector distribution chains. By
contrast, in this pilot Tibamal was distributed directly to retail
outlets in order to avoid contamination of the control arm; it is
possible that use of existing private sector distribution chains may
either improve or worsen retail sector availability, and the likely
impact on final retail prices is unclear. No mass media promotion
was used in the pilot, again to avoid contamination, though this
could be a major feature of AMF-m roll out, potentially enhancing
community awareness of AL availability and dosing. Finally, this
pilot included all medicine retailers including general stores;
however, most countries planning to implement AMF-m intend to
restrict the availability of subsidised AL to registered pharmacies
and in some cases drug stores. It is unclear how such a narrower
range of retail outlets will affect both uptake and adherence.
A number of key questions around ACT subsidy programmes
remain unanswered, above and beyond those of generalisability and
differences between this intervention design and that proposed by
AMF-m as described above. As noted above, even in the
intervention arm, the coverage of prompt ACT treatment of
44.9% remained well below the 80% RBM target, so the need to
identify additional strategies to increase coverage remains. A key
priority is improving accessibility in the public sector by
strengthening drug supply and reducing unofficial user fees. As
around a third of fevers are currently treated at public facilities,
increasing ACT dispensing to these cases has the potential to have a
major impact on treatment coverage. For those patients who find
public facilities inaccessible and even subsidized drugs in the retail
sector too expensive, it may be necessary to consider other
community-based strategies such as the use of CMDs. Moreover,
the retail sector intervention itself could have been further
strengthened by the use of mass media for promotion (not feasible
during this study due to the cluster-randomised design), stronger
enforcement of the monotherapy ban by the government, reduction
in Tibamal stock-outs, and/or training of a higher proportion of
retailers on Tibamal (a requirement for outlets stocking the
product). There were several potential reasons for the relatively
low proportion of outlets in the intervention area reporting trained
staff (43%) at follow-up. Some outlets identified for training were
unable to attend due to other commitments, or were closed when
training invitations were distributed. Others did not meet the
eligibility requirements for training at baseline (functioning for a
minimum of 6 months and selling an antimalarial or antipyretic
within the past year) but did meet these at follow-up, and many new
outlets appeared to have opened up, leading to an increase in
eligible outlets of 74 in the control arm and 126 in the intervention
arm between baseline and follow-up (Figure 1). This increase may
have been as a result of field workers becoming better at locating
outlets, or it could simply reflect the fluidity of the retail sector. All
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with most blaming insufficient funds. These issues highlight the
challenges of maintaining a trained cadre of AL retailers in such a
dynamic market.
There is concern that such strategies to increase retail sector
coverage could lead to substantial increases in overtreatment,
because many of those seeking ACTs in the private sector will not
be parasitaemic. As coverage increases, research is urgently
needed to assess how enhanced diagnosis—for example through
rapid diagnostic tests—can be implemented in the private retail
sector to limit use of antimalarial treatment to confirmed cases of
malaria. There is also concern about the capacity for appropriate
pharmacovigilance when ACTs are distributed more widely
outside formal facilities, and a need to evaluate strategies to
improve adherence to ACTs obtained from all sources. Finally, the
cost and cost-effectiveness of subsidy programmes should be
calculated and compared with other public sector and community-
based strategies for improving malaria treatment and prevention.
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Background. Malaria is a major global public-health
problem. Half the world’s population is at risk of this
mosquito-borne parasitic disease, which kills a million people
(mainly children living in sub-Saharan Africa) every year.
Although several parasites cause malaria, Plasmodium
falciparum is responsible for most of these deaths. For the
past 50 years, the main treatments for malaria have been
drugs such as sulfadoxine–pyrimethamine and chloroquine.
Unfortunately, parasitic resistance to these inexpensive
"monotherapies" is now widespread and there has been an
upsurge in the illness and death caused by P. falciparum.T o
combat this increase, the World Health Organization (WHO)
now recommends artemisinin-based combination therapy
(ACT) for first-line treatment of P. falciparum malaria in all
regions with drug-resistant malaria. In ACT, artemisinin
derivatives (new, fast-acting antimalarial drugs) are used in
combination with another antimalarial to reduce the chances
of P. falciparum becoming resistant to either drug.
Why Was This Study Done? Despite WHO’s recom-
mendation, ACT use in many developing countries remains
low partly because of its high retail price. To increase the
affordability of and access to ACT, the Global Fund to Fight
AIDS, Tuberculosis and Malaria is planning to run an ACT
subsidy mechanism called the ‘‘Affordable Medicines Facility
– malaria’’ (AMF-m). Using money provided by various
donors, the Global Fund aims to reduce the private sector
retail costs of ACT to those of monotherapies by making
"copayments" directly to ACT manufacturers. Phase I of the
AMF-m is already being implemented in pilots in several
countries, but there are few data on the likely impact of
private sector ACT subsidies on the coverage of prompt,
effective treatment at the community level. In this cluster
randomized controlled trial, the researchers investigate the
impact of an intervention package that includes ACT
subsidies on malaria treatment of young children in a high
malaria transmission area of western Kenya. In a cluster
randomized controlled trial, groups of patients rather than
individual patients are randomly assigned to receive a test or
control intervention, and the outcomes in different clusters
are compared.
What Did the Researchers Do and Find? The researchers
randomly assigned 18 rural sublocations (the lowest
administrative level in Kenya) to receive the intervention—
the provision of subsidized packs of the ACT artemether-
lumefantrine (AL) to retail outlets, retail staff training, and
community awareness activities—or to act as controls. The
researchers collected data about recent fever (a symptom of
malaria) in children aged 3–59 months and its treatment with
AL from randomly selected households in the intervention
and control sublocations 4 months before and 8 months
after roll-out of the intervention. At follow-up, 19.9% of
children in the control arm received AL within 24 hours of
fever developing compared to 5.3% of children at baseline (a
14.5% point rise). In the intervention arm, the percentage of
children receiving AL within 24 hours of fever developing
increased from 4.7% at baseline to 44.9% at follow-up (a
40.2% point rise). Moreover, the proportion of children
receiving AL in the intervention arm was significantly greater
than in the control arm (that is, unlikely to have happened by
chance). Put another way, the intervention more than
doubled the proportion of children with fever who
received AL promptly.
What Do These Findings Mean? These findings show
that in the rural areas of Kenya included in this study, the
provision of subsidized ACT in the private retail sector can
significantly increase the coverage of prompt and effective
treatment of fever in children with ACT; the increase in ACT
coverage in the control arm probably reflects improved
availability of AL in public-health facilities. However, these
findings may not be generalizable to other settings and,
because the design of this trial and that of the planned AMF-
m roll-out are somewhat different (through AMF-m,
subsidized drugs will be available to all age groups, for
example), these results must be used with caution when
trying to predict the outcome of AMF-m. Most importantly,
the tested intervention only achieved prompt ACT uptake in
44.9% of children with fever, somewhat lower than the
target of 80% set by the Roll Back Malaria Partnership. Thus,
although the provision of subsidized ACTs is likely to
improve ACT coverage, additional strategies to increase the
prompt use of ACT need to be identified.
Additional Information. Please access these Web sites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1000437.
N Information is available from the World Health Organiza-
tion on malaria (in several languages); the 2010 World
Malaria Report provides details of the current global
malaria situation
N The US Centers for Disease Control and Prevention provide
information on malaria (in English and Spanish)
N Information is available from the Roll Back Malaria
Partnership on the global control of malaria including fact
sheets about ACT and about malaria in Kenya, and
information on AMF-m
N The Global Fund to Fight AIDS, Tuberculosis and Malaria,
an international financing institution that invests the
world’s money to save lives, also has information on
fighting malaria and on the AMF-m (in several languages)
N MedlinePlus provides links to additional information on
malaria (in English and Spanish)
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